Introduction of New Therapeutic Substances

In table XW0, Introduction of Anatomical Regions, three new substance values were added for the substances listed below with the qualifier value B New Technology Group 11.Substances 0 Alpha1-proteinase Inhibitor 1 Anitocabtagene Autoleucel Immunotherapy 4 Somatic Stem Cells Substance values 0 Alpha 1-proteinase Inhibitor and 1 Anitocabtagene Autoleucel Immunotherapy, were added for the body part values 3 Peripheral Vein and 4 Central Vein. Substance value 4, Stem Cells, Somatic, was added to the body part value 5 Peripheral Artery.Alpha1-proteinase InhibitorAn alpha1-proteinase inhibitor (A1-PI) causes the retention of the alpha-1 antitrypsin (AAT) protein. A1-PI may be combined...

Subscribe or sign in to view the full article.

articles:   
Note:  The following article synopsis was NOT provided by the AHA. It was created by Find-A-Code/innoviHealth.

Article Overview

This article explains recent ICD-10-PCS updates involving new therapeutic substance values in a procedure table for anatomical region introduction. It is aimed at coding professionals who need to track structure changes, substance categories, and related clinical context across vascular access locations and therapy types. The discussion includes the update context, the affected body parts, and brief background on each therapy category.

Why This Topic Matters

Updates to procedure code tables can affect how therapy administration and related interventions are captured in coded records. Understanding these changes helps coding teams stay aligned with current table structure and recognize where new substance values apply.

Article Sections

  1. Update to table XW0

    Summarizes the table update and identifies the newly added substance values and body part applicability. The section establishes the scope of the coding change without detailing selection rules.

  2. Alpha1-proteinase Inhibitor

    Provides clinical background on this therapeutic substance and the general condition areas discussed in relation to it.

  3. Anitocabtagene Autoleucel Immunotherapy

    Describes the therapy category and its broad clinical context in hematologic treatment.

  4. Somatic Stem Cells

    Gives an overview of somatic stem cells and the general types of conditions mentioned as treatment areas.

What You Will Learn

  • What type of ICD-10-PCS table update is described
  • Which broad therapy categories were added to the table
  • How the article frames the affected anatomical regions and body parts
  • What clinical contexts are associated with the newly added substances

Who Should Read This

  • Medical coders
  • Coding auditors
  • Revenue cycle staff
  • Clinical documentation integrity specialists
  • Healthcare compliance teams

Subscribe or sign in to view the full article.

articles:   
  • The official AHA publication for ICD-10-CM and ICD-10-PCS coding guidelines and advice
  • Current newsletters added each quarter
  • Full Archives - over 3100 articles
  • ALL years/issues back to 1984 organized by year and issue
  • Includes ICD-10-CM/PCS Articles since 2013
  • Fully searchable through Find-A-Code's Comprehensive Search
  • Codes mentioned in articles are linked to Code Information pages
  • Code Information pages link back to related articles
  • View all the articles associated with any code, right from the code page!
Access to this feature is available in the following products:
  • AHA's Coding Clinic® - ICD-10-CM/PCS +Archives

demo
request yours today
 subscribe
start today
 newsletter
free subscription

Thank you for choosing Find-A-Code, please Sign In to remove ads.

Aimee- AI -powered coding assistant - Try it now for Free Would you like Aimee - AI
to help you with this?